The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial

(2021) Luis Paz-Ares et al.   LANCET ONCOLOGY

Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50%

(2020) Alessio Cortellini et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Neutrophil-to-lymphocyte ratio and lactate dehydrogenase as biomarkers for urothelial cancer treated with immunotherapy

(2020) G. L. Banna et al.   Clinical & Translational Oncology

Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes

(2020) Alessio Cortellini et al.   Clinical Lung Cancer

Neutrophil-to-lymphocyte ratio in combination with PD-L1 or lactate dehydrogenase as biomarkers for high PD-L1 non-small cell lung cancer treated with first-line pembrolizumab

(2020) Giuseppe Luigi Banna et al.   Translational Lung Cancer Research

Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater

(2019) Martin Reck et al.   JOURNAL OF CLINICAL ONCOLOGY

First-line Pembrolizumab vs. Pembrolizumab plus Chemotherapy vs. Chemotherapy alone in Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-analysis

(2019) Ryul Kim et al.   Clinical Lung Cancer

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

(2019) Tony S K Mok et al.   LANCET

Tumor Mutation Burden—From Hopes to Doubts

(2019) Alfredo Addeo et al.   JAMA Oncology

Chemotherapy in Combination With Immune Checkpoint Inhibitors for the First-Line Treatment of Patients With Advanced Non-small Cell Lung Cancer: A Systematic Review and Literature-Based Meta-Analysis

(2019) Alfredo Addeo et al.   Frontiers in Oncology

A Novel Paradigm Between Leukocytosis, G-CSF Secretion, Neutrophil-to-Lymphocyte Ratio, Myeloid-Derived Suppressor Cells, and Prognosis in Non-small Cell Lung Cancer

(2019) Montreh Tavakkoli et al.   Frontiers in Oncology

Tumour-associated neutrophils in patients with cancer

(2019) Merav E. Shaul et al.   Nature Reviews Clinical Oncology

Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer

(2019) Matthew D. Hellmann et al.   NEW ENGLAND JOURNAL OF MEDICINE

Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression

(2019) E J Aguilar et al.   ANNALS OF ONCOLOGY

The Significance of the PD-L1 Expression in Non–Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers

(2018) Kazuki Takada et al.   Clinical Lung Cancer

Immune-checkpoint inhibitors in non-small cell lung cancer: A tool to improve patients’ selection

(2018) Giuseppe Luigi Banna et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non–Small Cell Lung Cancer

(2018) Laura Mezquita et al.   JAMA Oncology

Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer

(2017) Stephen J. Bagley et al.   LUNG CANCER

Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab

(2016) P. F. Ferrucci et al.   ANNALS OF ONCOLOGY

Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab

(2016) Benjamin Weide et al.   CLINICAL CANCER RESEARCH

Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients

(2015) P F Ferrucci et al.   BRITISH JOURNAL OF CANCER

Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma

(2014) Ester Simeone et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER